FDA Approves Bemotrizinol, Expanding Sunscreen Options for U.S. Consumers

Key points

• The FDA has approved bemotrizinol as a new sunscreen active ingredient in the United States.
• Bemotrizinol is already approved for use in Europe and Japan, but this is its first approval in the U.S.
• The approval provides consumers with an additional choice for UV protection, potentially enhancing skin cancer prevention efforts.
• Bemotrizinol is known for its broad-spectrum UV protection and stability, making it a valuable addition to the sunscreen market.

Background

This development follows a trend of increasing cosmetic and dermatological procedures in the U.S., as noted in a September 2026 report by the American Society of Plastic Surgeons, which showed a 7% rise in cosmetic procedures from 2024 to 2025. While the report focused on minimally invasive treatments like Botox and fillers, the approval of a new sunscreen ingredient underscores a broader public interest in skin health and protection. The approval of bemotrizinol adds to the growing array of options for consumers seeking to protect their skin from UV damage, complementing other preventive measures.

Why it matters

The approval of bemotrizinol expands the range of sunscreen options available to U.S. consumers, potentially improving access to effective UV protection. This is significant for skin cancer prevention, as consistent use of sunscreen is a key strategy in reducing the risk of skin cancer. The addition of a new ingredient may also drive innovation in the sunscreen market, leading to more effective and user-friendly products.

What to watch

Manufacturers are expected to begin incorporating bemotrizinol into new and existing sunscreen products in the coming months. Consumer awareness and adoption of sunscreens containing bemotrizinol will likely increase as products hit the market. Regulatory bodies may also monitor the safety and efficacy of bemotrizinol in real-world use to ensure it meets the high standards set by the FDA.